戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 -chain (AL) amyloidosis is a rare, incurable plasma cell disorder.
2 ry systemic amyloidosis (AL) is an incurable plasma cell disorder.
3 Primary systemic amyloidosis (AL) is a fatal plasma cell disorder.
4 loma, primary amyloidosis (AL), or a related plasma cell disorder.
5 cance (MGUS) is an asymptomatic premalignant plasma cell disorder.
6 iple myeloma (SMM) is an asymptomatic clonal plasma cell disorder.
7 ons were identified in sixteen patients with plasma cell disorders.
8 entary to conventional methods of evaluating plasma cell disorders.
9 plant had complete responses of their clonal plasma cell disorders.
10 om had biopsy-proven amyloidosis with clonal plasma cell disorders.
11 al light chain deposits is a complication of plasma cell disorders.
12 tablished in the diagnosis and monitoring of plasma cell disorders.
13  leukemia/myelodysplastic syndrome (45%) and plasma cell disorders (38.8%).
14                   Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of
15 termined significance (MGUS), a premalignant plasma-cell disorder, among persons 50 years of age or o
16 hy, organomegaly, endocrinopathy, monoclonal plasma cell disorder and skin changes).
17 icant RFs for death included lymphoma versus plasma cell disorders and SOT type; thoracic and liver S
18   Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal
19 he polyradiculoneuropathy and the monoclonal plasma cell disorder, and at least 1 of the other 3 majo
20 mplete response or persistence of the clonal plasma cell disorder, and change in the function of orga
21 ents have experienced relapses of the clonal plasma cell disorder at 12 and 24 months.
22 is while receiving proteasome inhibitors for plasma cell disorders at Mount Sinai Hospital in New Yor
23 opathy, and skin changes) syndrome is a rare plasma cell disorder characterized by demyelinating peri
24 noglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ
25 a of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International My
26            Multiple myeloma (MM) is a clonal plasma cell disorder frequently accompanied by hematopoi
27 he proportion of patients with a preexisting plasma cell disorder has never been determined by labora
28 phomas (HR, 1.81; 95% CI, 1.12 to 2.93), and plasma cell disorders (HR, 2.42; 95% CI, 1.08 to 5.41),
29 loid light-chain) amyloidosis is an uncommon plasma cell disorder in which depositions of amyloid lig
30 hain amyloidosis, a clonal non-proliferative plasma cell disorder in which fragments of immunoglobuli
31  in patients with multiple myeloma and other plasma cell disorders, including smouldering multiple my
32 is occurs in myeloma, but not in the limited plasma cell disorder monoclonal gammopathy of unknown si
33                                  Preexisting plasma cell disorders, monoclonal gammopathy of undeterm
34 ard of care for this disease and the related plasma cell disorder multiple myeloma, due to upregulati
35 ith a higher risk of mortality compared with plasma cell disorder or myeloma (2.41, [1.08-5.38]; p=0.
36 ic syndrome (5 of 18 [28%]), those involving plasma cell disorders or multiple myeloma (16 of 27 [59%
37 c syndrome (18 of 28 [64%]), those involving plasma cell disorders or multiple myeloma (27 of 30 [90%
38 esses to multiple myeloma or another related plasma cell disorder (PCD) at a rate of approximately 1%
39 ized by peripheral neuropathy (PN), a clonal plasma cell disorder (PCD), organomegaly, endocrinopathy
40 enotype is associated with the initiation of plasma-cell disorders rather than the progression of MGU
41 hy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MC
42 have also been shown to be prognostic in all plasma cell disorders tested.
43                   Multiple myeloma (MM) is a plasma cell disorder that potentially initiates during a
44  we analyzed >10 000 patients with different plasma cell disorders to describe the RAS/RAF landscape.
45 sis was corroborated in patients with clonal plasma cell disorders, where NK cells that stained for P
46 asma cell leukaemia is a rare and aggressive plasma cell disorder with a poor prognosis.
47 will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison